Skip to main content

SYNAPTIC MECHANISMS IN PSYCHIATRIC DISORDERS: POTENTIAL TARGETS FOR NOVEL DRUG DEVELOPMENT

RYC-2016-19282

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Incorporación
Call Ramón y Cajal
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DEL PAIS VASCO EUSKAL HERRIKO UNIBERTSITATEA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effects of Gαi2 and Gαz protein knockdown on alpha2A-adrenergic and cannabinoid CB1 receptor regulation of MEK-ERK and FADD pathways in mouse cerebral cortex

  • Ramos-Miguel, A.
  • Sánchez-Blázquez, Pilar
  • García-Sevilla, Jesús Andrés
Background: Alpha-adrenergic (α-AR) and cannabinoid CB (CB-R) receptors exert their functions modulating multiple signaling pathways, including MEK-ERK (extracellular signal-regulated kinases) and FADD (Fas-associated protein with death domain) cascades. These molecules are relevant in finding biased agonists with fewer side effects, but the mechanisms involving their modulations by α-AR- and CB-R in vivo are unclear. This study investigated the roles of Gαi and Gαz proteins in mediating α-AR- and CB-R-induced alterations of MEK-ERK and FADD phosphorylation (p-) in mouse brain cortex. Methods: Gαi or Gαz protein knockdown was induced in mice with selective antisense oligodeoxinucleotides (ODNs; 3 nmol/day, 5 days) prior to UK-14,304 (UK or brimonidine; 1 mg/kg) or WIN55212-2 (WIN; 8 mg/kg) acute treatments. Inactivated (p-T) MEK1, activated (p-S) MEK1/2, activated (p-T/Y) ERK1/2, p-S FADD, and the corresponding total forms of these proteins were quantified by immunoblotting. Results: Increased (+ 88%) p-T MEK1 cortical density, with a concomitant reduction (–43%) of activated ERK was observed in UK-treated mice. Both effects were attenuated by Gαi or Gαz antisense ODNs. Contrastingly, WIN induced Gαi- and Gαz-independent upregulations of p-T MEK1 (+ 63%), p-S MEK1/2 (+ 86%), and activated ERK (+ 111%) in brain. Pro-apoptotic FADD was downregulated (− 34 to 39%) following UK and WIN administration, whereas the neuroprotective p-S FADD was increased (+ 74%) in WIN-treated mice only. None of these latter effects required from Gαi or Gαz protein integrity. Conclusion: The results indicate that α-AR (UK), but not CB-R (WIN), agonists use Gαi and Gαz proteins to modulate MEK-ERK, but not FADD, pathway in mouse brain cortex., The study was supported by grants RTI2018-094414-A-I00 (AR-M), SAF2011-29918 (JAG-S), and RT 2018-093677-B-100 (PSB) from the Spanish Ministry of Science, Innovation and Universities (MCIU) and the European Regional Development Fund (ERDF). AR-M is a ‘Ramón y Cajal’ Researcher (grant RYC-2016-19282) supported by MCIU. JAG-S is a member of the Institut d’Estudis Catalans (Barcelona, Catalonia, Spain). None of the above funding agencies took part in the elaboration of the study, formulation of the hypotheses, or interpretation of the results.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effects of Gαi2 and Gαz protein knockdown on alpha2A-adrenergic and cannabinoid CB1 receptor regulation of MEK-ERK and FADD pathways in mouse cerebral cortex

  • Robles-Ramos, Miguel A.
  • Sánchez-Blázquez, Pilar
  • García-Sevilla, Jesús Andrés
Background: Alpha-adrenergic (α-AR) and cannabinoid CB (CB-R) receptors exert their functions modulating multiple signaling pathways, including MEK-ERK (extracellular signal-regulated kinases) and FADD (Fas-associated protein with death domain) cascades. These molecules are relevant in finding biased agonists with fewer side effects, but the mechanisms involving their modulations by α-AR- and CB-R in vivo are unclear. This study investigated the roles of Gαi and Gαz proteins in mediating α-AR- and CB-R-induced alterations of MEK-ERK and FADD phosphorylation (p-) in mouse brain cortex. Methods: Gαi or Gαz protein knockdown was induced in mice with selective antisense oligodeoxinucleotides (ODNs; 3 nmol/day, 5 days) prior to UK-14,304 (UK or brimonidine; 1 mg/kg) or WIN55212-2 (WIN; 8 mg/kg) acute treatments. Inactivated (p-T) MEK1, activated (p-S) MEK1/2, activated (p-T/Y) ERK1/2, p-S FADD, and the corresponding total forms of these proteins were quantified by immunoblotting. Results: Increased (+ 88%) p-T MEK1 cortical density, with a concomitant reduction (–43%) of activated ERK was observed in UK-treated mice. Both effects were attenuated by Gαi or Gαz antisense ODNs. Contrastingly, WIN induced Gαi- and Gαz-independent upregulations of p-T MEK1 (+ 63%), p-S MEK1/2 (+ 86%), and activated ERK (+ 111%) in brain. Pro-apoptotic FADD was downregulated (− 34 to 39%) following UK and WIN administration, whereas the neuroprotective p-S FADD was increased (+ 74%) in WIN-treated mice only. None of these latter effects required from Gαi or Gαz protein integrity. Conclusion: The results indicate that α-AR (UK), but not CB-R (WIN), agonists use Gαi and Gαz proteins to modulate MEK-ERK, but not FADD, pathway in mouse brain cortex., The study was supported by grants RTI2018-094414-A-I00 (AR-M), SAF2011-29918 (JAG-S), and RT 2018-093677-B-100 (PSB) from the Spanish Ministry of Science, Innovation and Universities (MCIU) and the European Regional Development Fund (ERDF). AR-M is a ‘Ramón y Cajal’ Researcher (grant RYC-2016-19282) supported by MCIU. JAG-S is a member of the Institut d’Estudis Catalans (Barcelona, Catalonia, Spain). None of the above funding agencies took part in the elaboration of the study, formulation of the hypotheses, or interpretation of the results.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Regulation of cortico-thalamic JNK1/2 and ERK1/2 MAPKs and apoptosis-related signaling pathways in PDYN gene-deficient mice following acute and chronic mild stress

  • Yáñez-Gómez, Fernando
  • Ramos-Miguel, Alfredo
  • García-Sevilla, Jesús Andrés
  • Manzanares, Jorge
  • Femenía, Teresa
This article belongs to the Special Issue Involvement of the MAPK Pathway in Cancer and Immunology., The crosstalk between the opioidergic system and mitogen-activated protein kinases (MAPKs) has a critical role in mediating stress-induced behaviors related to the pathophysiology of anxiety. The present study evaluated the basal status and stress-induced alterations of cortico-thalamic MAPKs and other cell fate-related signaling pathways potentially underlying the anxiogenic endophenotype of PDYN gene-deficient mice. Compared to littermates, PDYN knockout (KO) mice had lower cortical and or thalamic amounts of the phospho-activated MAPKs c-Jun N-terminal kinase (JNK1/2) and extracellular signal-regulated kinase (ERK1/2). Similarly, PDYN-KO animals displayed reduced cortico-thalamic densities of total and phosphorylated (at Ser191) species of the cell fate regulator Fas-associated protein with death domain (FADD) without alterations in the Fas receptor. Exposure to acute restraint and chronic mild stress stimuli induced the robust stimulation of JNK1/2 and ERK1/2 MAPKs, FADD, and Akt-mTOR pathways, without apparent increases in apoptotic rates. Interestingly, PDYN deficiency prevented stress-induced JNK1/2 and FADD but not ERK1/2 or Akt-mTOR hyperactivations. These findings suggest that cortico-thalamic MAPK- and FADD-dependent neuroplasticity might be altered in PDYN-KO mice. In addition, the results also indicate that the PDYN gene (and hence dynorphin release) may be required to stimulate JNK1/2 and FADD (but not ERK1/2 or Akt/mTOR) pathways under environmental stress conditions., This joint research was funded by Red Temática de Investigación Cooperativa en Salud–Red de Trastornos Adictivos (RETICS–RTA, Instituto de Salud Carlos III [ISCIII], MCIU/AEI/FEDER), Grupos RD06/0001/0004 (J.M.) and RD06/0001/0003 (J.A.G.-S.). J.M. also received financial support from Proyectos de Investigación en Salud—ISCIII (grant RD. PI18/00576), Red de Investigación en Atención Primaria de Adicciones (grant RD21/0009/0008), and Delegación del Gobierno para el Plan Nacional Sobre Drogas (PNSD, grant 2019I012) from the Spanish Ministry of Health (MSC). This study was also supported by MCIU/AEI/FEDER (grants RTI2018-094414-A-I00 to A.R.-M., PID2019-109323RA-I00 to T.F., and SAF2008-01311 to J.A.G.-S.), and MSC/FEDER (FIS 05/0429 to J.M). A.R.-M. (grant RYC-2016-19282) and T.F. (grant RYC-2017-22666) are ‘Ramón y Cajal’ Researchers., Peer reviewed